Chinese Journal of Lung Cancer (Mar 2021)
Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
- Jun NI,
- Miao HUANG,
- Li ZHANG,
- Nan WU,
- Chunxue BAI,
- Liang’an CHEN,
- Jun LIANG,
- Qian LIU,
- Jie WANG,
- Yilong WU,
- Fengchun ZHANG,
- Shuyang ZHANG,
- Chun CHEN,
- Jun CHEN,
- Wentao FANG,
- Shugeng GAO,
- Jian HU,
- Tao JIANG,
- Shanqing LI,
- Hecheng LI,
- Yongde LIAO,
- Yang LIU,
- Deruo LIU,
- Hongxu LIU,
- Jianyang LIU,
- Lunxu LIU,
- Mengzhao WANG,
- Changli WANG,
- Fan YANG,
- Yue YANG,
- Lanjun ZHANG,
- Xiuyi ZHI,
- Wenzhao ZHONG,
- Yuzhou GUAN,
- Xiaoxiao GUO,
- Chunxia HE,
- Shaolei LI,
- Yue LI,
- Naixin LIANG,
- Fangliang LU,
- Chao LV,
- Wei LV,
- Xiaoyan SI,
- Fengwei TAN,
- Hanping WANG,
- Jiangshan WANG,
- Shi YAN,
- Huaxia YANG,
- Huijuan ZHU,
- Junling ZHUANG,
- Minglei ZHUO
Affiliations
- Jun NI
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Miao HUANG
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Li ZHANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Nan WU
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Chunxue BAI
- Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Liang’an CHEN
- The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
- Jun LIANG
- Peking University International Hospital, Beijing 102206, China
- Qian LIU
- Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China
- Jie WANG
- State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Yilong WU
- Department of Pulmonary Cancer, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510000, China
- Fengchun ZHANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Shuyang ZHANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Chun CHEN
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China
- Jun CHEN
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin 300052, China
- Wentao FANG
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
- Shugeng GAO
- State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Jian HU
- Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
- Tao JIANG
- Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, China
- Shanqing LI
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Hecheng LI
- Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Yongde LIAO
- Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei 430022, China
- Yang LIU
- The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
- Deruo LIU
- China-Japan Friendship Hospital, Beijing 100029, China
- Hongxu LIU
- Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110001, China
- Jianyang LIU
- Department of Thoracic Surgery-1, Jilin Cancer Hospital, Changchun 130012, China
- Lunxu LIU
- Department of Cardiovascular and Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
- Mengzhao WANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Changli WANG
- Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China
- Fan YANG
- Peking University People’s Hospital, Beijing 100044, China
- Yue YANG
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Lanjun ZHANG
- Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
- Xiuyi ZHI
- Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
- Wenzhao ZHONG
- Department of Pulmonary Cancer, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510000, China
- Yuzhou GUAN
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Xiaoxiao GUO
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Chunxia HE
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Shaolei LI
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Yue LI
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Naixin LIANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Fangliang LU
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Chao LV
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Wei LV
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Xiaoyan SI
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Fengwei TAN
- State Key Laboratory of Molecular Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Hanping WANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Jiangshan WANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Shi YAN
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- Huaxia YANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Huijuan ZHU
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Junling ZHUANG
- Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Minglei ZHUO
- Department of Thoracic Surgery, Peking University Cancer Hospital, Beijing 100142, China
- DOI
- https://doi.org/10.3779/j.issn.1009-3419.2021.101.06
- Journal volume & issue
-
Vol. 24,
no. 3
pp. 141 – 160
Abstract
Background and objective Perioperative treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancelation of surgery, additional illness, and even death, and have therefore attracted much attention. The purpose of the clinical recommendations is to form a diagnosis and treatment plan suitable for the current domestic medical situation for the immune-related adverse event (irAE). Methods This recommendation is composed of experts in thoracic surgery, oncologists, thoracic medicine and irAE related departments (gastroenterology, respirology, cardiology, infectious medicine, hematology, endocrinology, rheumatology, neurology, dermatology, emergency section) to jointly complete the formulation. Experts make full reference to the irAE guidelines, large-scale clinical research data published by thoracic surgery, and the clinical experience of domestic doctors and publicly published cases, and repeated discussions in multiple disciplines to form this recommendation for perioperative irAE. Results This clinical recommendation covers the whole process of prevention, evaluation, examination, treatment and monitoring related to irAE, so as to guide the clinical work comprehensively and effectively. Conclusion Perioperative irAE management is an important part of immune perioperative treatment of lung cancer. With the continuous development of immune perioperative treatment, more research is needed in the future to optimize the diagnosis and treatment of perioperative irAE.
Keywords
- lung neoplasms
- perioperative immunotherapy
- immune checkpoint inhibitor related adverse events
- clinical recommendation
